Arecor CEO on AT278 partnership with Sequel Med Tech, $11m royalty funding deal and interim results

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s strategic updates, including a key partnership with Sequel Med Tech and a new royalty financing agreement with Ligand Pharmaceuticals. Howell explained that Arecor has partnered with Sequel, a US-based insulin pump device company, to advance its lead program AT278, described as “the only ultra-concentrated, ultra-rapid acting insulin in development.” Together, the companies will co-develop AT278 in combination with Sequel’s twiist automated insulin delivery system, with phase 2 clinical trial preparations already underway. Each party has committed up to $1.3 million to fund development, with trial readiness targeted for 2026. Discussing the rationale for the partnership, Howell said Sequel “really bring innovation to the table, significant experience in terms of patient need, the market and also clearly commercialisation.” She noted the potential for AT278 and the Twist system to extend insulin pump wear times and support future miniaturisation, expanding access for people with diabetes. In addition, Arecor announced a royalty financing deal with Ligand Pharmaceuticals, securing up to $11 million in non-dilutive funding linked to partnered products using its Arestat technology. Howell said this extends the company’s cash runway into the first half of 2027, while supporting development of AT278 and its oral peptide delivery platform. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #ArecorTherapeutics #AT278 #DiabetesCare #InsulinPump #SequelMedTech #TwistSystem #DiabetesTechnology #BiotechNews #PharmaUpdates #ClinicalTrials